Summary

A recent study has identified a surprising factor in the advancement of Alzheimer’s disease: the immune molecule STING. Researchers discovered that while STING typically helps protect the brain, it becomes overly active as we age, leading to damaging inflammation and hastening brain deterioration.

In experiments on mice, inhibiting STING stopped the formation of harmful plaques and tangles, maintaining cognitive abilities. This significant discovery positions STING as a potential target for treatments not only for Alzheimer’s but also for other neurodegenerative conditions such as ALS and Parkinson’s disease.

Key Facts

• STING Activation: Damage to DNA as we age activates STING, resulting in harmful inflammation in the brain and injury to neurons.
• Therapeutic Target: Blocking STING in mouse models reduced plaque buildup, safeguarded neurons, and enhanced memory.
• Broader Relevance: STING may also be involved in conditions like Parkinson’s, ALS, and dementia, representing a new avenue for treatment.

About the Research

This new perspective on Alzheimer’s disease has unveiled a potential breakthrough in tackling cognitive decline associated with Alzheimer’s and other neurodegenerative disorders. Scientists from the University of Virginia School of Medicine have been exploring how Alzheimer’s may stem from misguided immune responses to DNA damage in the brain.

Their findings suggest that the immune molecule STING encourages the development of the detrimental plaques and protein tangles linked to Alzheimer’s. By inhibiting this molecule, they were able to shield lab mice from mental deterioration.

As a pivotal element of the brain’s immune defense, STING might also contribute significantly to Parkinson’s disease, ALS, and various types of dementia, implying that moderating its activity could benefit numerous patients facing severe conditions.

“Our results show that the DNA damage accumulating with age activates STING, which mediates inflammation and neuronal damage in Alzheimer’s patients,” noted researcher John Lukens, PhD, director at UVA’s Harrison Family Translational Research Center in Alzheimer’s and Neurodegenerative Diseases.

“These insights help explain the heightened risk of Alzheimer’s with age and unveil a unique avenue for therapeutic intervention for neurodegenerative diseases.”

Alarming Trends in Alzheimer’s

Alzheimer’s is increasingly becoming a pressing issue, with over 7 million Americans currently affected, a figure that could rise to over 13 million by 2050. This urgency drives researchers to actively seek better methods to understand and manage the disease.

The exact causes of Alzheimer’s remain somewhat unclear; however, there’s a growing recognition of the immune system’s impact on its progression. STING plays a part in this immune response, helping eliminate viruses and cells with damaged DNA.

Though STING serves as a vital defender, its excessive activation can lead to harmful inflammation and tissue harm. This realization prompted Lukens and his team to investigate its role in Alzheimer’s.

By blocking STING in lab mice, they observed a halt in the formation of Alzheimer’s plaques, modifications to the immune cells known as microglia, and changes in significant gene activity, among other benefits.

“We found that inhibiting STING reduced microglial activation near plaques, preserved neighboring neurons from damage, and improved memory in Alzheimer’s model mice,” stated Jessica Thanos from UVA’s Department of Neuroscience and Center for Brain Immunology and Glia.

“These findings suggest that STING triggers harmful immune reactions in the brain, worsening neuronal damage and advancing cognitive decline in Alzheimer’s disease.”

Promising Treatment Target

While various molecules have been explored for their roles in Alzheimer’s, STING stands out as a particularly viable target for treatment development, according to researchers at UVA Health. Blocking STING appears to impede both amyloid plaque accumulation and tau tangle formation, both of which are significant in Alzheimer’s pathology.

Other molecules don’t show such consistent involvement and might only be targetable at specific, limited phases of the disease’s development.

“We are just beginning to grasp the intricate roles of innate immune activation in the brain, particularly during normal and pathological aging,” Thanos commented. “Identifying the cells and signals that sustain this activation will vastly improve our capacity to intervene effectively.”

Although Lukens’ groundbreaking work is paving the way for advancements against Alzheimer’s, further research is needed to translate these findings into real-world treatments.

Understanding the various roles of STING in the body—like its involvement in the immune response to cancer—will be critical to ensure new treatments don’t have unintended side effects.

Still, these are the essential questions Lukens and his colleagues at the Harrison Family Translational Research Center are keen to explore as they aim to accelerate new treatments and aspire for eventual cures. “We hope this research brings us closer to identifying safer, more effective means to protect the aging brain, with an urgent need for therapies that can halt or prevent neuronal damage in Alzheimer’s,” Lukens remarked.

“Illuminating how STING contributes to neuronal damage may lead us to similar targets and ultimately, effective treatments.”

Findings Published

The results have been shared in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.

The research team included Thanos, Olivia C. Campbell, Maureen N. Cowan, Katherine R. Bruch, Katelyn A. Moore, Hannah E. Ennerfelt, Nick R. Natale, Aman Mangalmurti, Nagaraj Kerur, and Lukens. The scientists have no financial ties to this work.

Funding was provided by the National Institutes of Health’s National Institute on Aging, along with grants from the Alzheimer’s Association, Cure Alzheimer’s Fund, The Owens Family Foundation, and The Harrison Family Foundation.